



## PRESS RELEASE

### **CARMAT to present the positive interim results of the first part of the PIVOTAL study at the 39<sup>th</sup> ISHLT annual meeting in Orlando, Florida**

To date, the CARMAT total artificial heart has achieved a record 13 months of continuous individual support within the framework of the study

**Paris, March 28, 2019 – 7.00 am CET**

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced its participation to the 39<sup>th</sup> annual meeting of the [ISHLT – International Society for Heart & Lung Transplantation](#), one of the world's largest forums in this field, which will take place in Orlando, Florida, from April 3 to 6, 2019.

At this event, Dr. Piet Jansen, Medical Director of CARMAT, will present the positive interim results of the first part of the PIVOTAL study, published last January, during the "Advances in Short- and Long-Term Mechanical Circulatory Support - What's Next?" symposium.

*"The ISHLT annual meeting is an excellent platform to share the clinical results of the first cohort of 10 patients included in the PIVOTAL study with international cardiology experts. Our previous publication in the Journal of Heart and Lung Transplantation, the official journal of the ISHLT, which focused on data from our feasibility study, generated much enthusiasm, and we are delighted to be able to provide new clinical elements to further support, with more hindsight, the potential benefits of the CARMAT TAH for treating patients suffering from end-stage biventricular heart failure. To date, we are pleased to announce that our prosthesis has achieved, within the framework of the PIVOTAL study, a record 13 months of individual support, and 5 years 10 months of cumulative support in the 11 implanted patients", said Dr. Piet Jansen, Medical Director of CARMAT.*

**Pr. Ivan Netuka, Professor of Cardiac Surgery and Chairman of the Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic and Principal Investigator of the second cohort of the PIVOTAL study, commented:** *"The support experience exceeding one year in our patient provides him an enjoyable life at his home environment and offers a viable therapeutic alternative for patients not eligible to receive a donor heart".*

#### **Information on the Session:**

Symposium: Advances in Short- and Long-Term Mechanical Circulatory Support - What's Next?

Session: The Future of Total Heart Replacement – CARMAT Perspective

Date: Thursday April 4, 2019

Time: 4:55 – 5:15 pm

Location: Loews Meeting Complex, Grand Caribbean 1-7

...

**CARMAT**  
**Stéphane Piat**  
Chief Executive Officer

**Pascale d'Arbonneau**  
Chief Financial Officer  
Tel.: +33 1 39 45 64 50  
[contact@carmatsas.com](mailto:contact@carmatsas.com)

**Alize RP**  
Press Relations

**Caroline Carmagnol**

Tel.: +33 1 44 54 36 66  
[carmat@alizerp.com](mailto:carmat@alizerp.com)



**NewCap**  
Investor Relations &  
Strategic Communication

**Dusan Oresansky**  
**Alexia Faure**

Tel.: +33 1 44 71 94 94  
[carmat@newcap.eu](mailto:carmat@newcap.eu)

Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**

...

#### **DISCLAIMER**

*This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.*

*No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registration document filed with the Autorité des Marchés Financiers under number D.19-0135 on March 12, 2019, as well as changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials.*